Low Risk Prostate Cancer: Active Surveillance vs Treatment

Your biopsy showed prostate cancer, and your urologist called it low risk. Then they mentioned active surveillance, and you may be thinking: why would anyone watch a cancer instead of removing it? It is a fair question. This guide explains what low risk means, what the best trial found, and how to weigh your options.

What low risk prostate cancer means

Many prostate cancers grow very slowly. Some never grow enough to cause symptoms or shorten life. Doctors use a few facts to group prostate cancer by risk. [3]

• Grade Group 1, also called Gleason score 6. This is the lowest grade.
• PSA (prostate-specific antigen, a blood test) below 10.
• A tumor that is small and limited to the prostate, based on the exam and imaging.

A cancer with all three features is usually called low risk. Some guidelines also use a "very low risk" group, based on how much cancer was in the biopsy samples.

The options

Active surveillance

Active surveillance means watching the cancer closely, with a plan to treat it if it changes. [3] It usually includes:

• PSA tests every few months.
• Regular rectal exams.
• MRI scans of the prostate.
• Repeat biopsies on a schedule.

The goal is to avoid or delay treatment side effects, while keeping the chance to cure the cancer if it grows.

Watchful waiting

Watchful waiting is different. It is less intense and is mostly for older men or men with other serious health problems. It treats symptoms if they appear, rather than trying to cure the cancer. [3]

Surgery or radiation

Radical prostatectomy removes the prostate. Radiation therapy uses beams or implanted seeds to kill cancer cells. Both aim to cure the cancer. [3]

What your doctor looks at

What the ProtecT trial found

The best evidence comes from the ProtecT trial in the United Kingdom. It assigned 1,643 men with prostate cancer found by PSA testing to active monitoring, surgery, or radiation. Researchers followed them for a median of 15 years. [1]

• Death from prostate cancer was low in all three groups: about 3 in 100 men. The differences between groups were small and could be due to chance. [1]
• Death from any cause was similar across groups. [1]
• Cancer spread (metastasis) was more common with monitoring: about 9 in 100 men, compared with about 5 in 100 with surgery or radiation. [1]
• More than half of men in the monitoring group had surgery or radiation at some point during the 15 years. [1]

Two points help put these numbers in context. First, the monitoring in ProtecT was less intense than modern active surveillance, which uses MRI and more planned biopsies. Second, many men in the trial had intermediate risk cancer, not only low risk. [1]

Side effects

Men in the trial reported how treatment affected their daily life. [2]

• Surgery caused the most problems with urine leakage and erections.
• Radiation caused more bowel problems at first, and also affected erections.
• Monitoring avoided these effects at first, but some men had them later if they had treatment.

What guidelines say

In both Canada and the US, urology and cancer guidelines support active surveillance as the preferred choice for most men with low risk prostate cancer. Surgery or radiation remain options for men who prefer them after a full discussion. Choices are more varied for intermediate risk cancer.

How this links to screening

Low risk cancers are often found through PSA screening. This is one reason screening is debated. The US Preventive Services Task Force calls PSA screening for men aged 55 to 69 an individual decision, and it notes that overdiagnosis and overtreatment are key harms. [4] The former Canadian Task Force on Preventive Health Care recommended against PSA screening. Active surveillance helps lower the harm of overtreatment when a low risk cancer is found.

How to weigh the choice

There is no single right answer. Your choice depends on your values. Think about:

• How you feel about living with a cancer that is being watched.
• How much you want to avoid urinary, sexual, or bowel side effects.
• Your age and other health conditions.
• Whether you can keep up with regular tests and visits.

Living with active surveillance

Some men find it hard to live with a cancer that is not removed. This feeling is normal. It often gets easier with time, as test results stay stable.

• Keep a list of your PSA results and biopsy dates, so you can see trends.
• Ask your team who to call with questions between visits.
• Bring your partner or a friend to key visits.
• Ask about support groups for men with prostate cancer.
• Keep up with general health habits, such as physical activity and not smoking.

If worry starts to affect your sleep, work, or relationships, tell your team. Choosing treatment because of worry is a valid choice, as long as you understand the trade-offs.

Questions to ask your clinician

• What is my Grade Group, PSA level, and stage?
• Am I low risk or intermediate risk, and why?
• What would my active surveillance schedule look like?
• What changes would make you recommend treatment?
• What are my chances of side effects with surgery or radiation?
• Should I get an opinion from both a urologist and a radiation oncologist?
• Are genetic tests on my tumor or my family history relevant for me?

Bottom line

For most men with low risk prostate cancer, active surveillance is a safe and widely recommended choice. In the largest trial, about 3 in 100 men died of prostate cancer within 15 years, whatever the first choice was. Treatment lowered the chance of spread but caused more side effects. Talk with your team about what matters most to you.

Primary AI can show you the guideline and study sources behind this topic in plain language, so you can bring better questions to your appointment.